Inato provides a platform for community-based clinical researchers and pharmaceutical companies to aid in the selection of patients for clinical trials.
The company announced that it launched its new ‘Check Your Fit’ tool, which allows sites and pharma sponsors to take an assessment to determine whether they are a good match for a specific trial.
According to the company, the assessment tool helps sites avoid wasted time to advance with a clinical trial opportunity that is not the right fit or their community of patients.
The new service allows for research sites to reuse their data from one trial to another through the use of a pre-fill feature to reuse information from similar past enrolment plans.
The company states that its platform allows an enrolment rate five times higher than non-Inato sites. Inato also notes that its diversity enrolment rates are more than two times higher, a feature that is of growing importance across the industry.
One of Inato’s partners is Clinical Trials Management Services, which is a California-based investigator site for all study phases. As part of its combination with Inato, the site provides a patient database made up of 50% racially and ethnically diverse populations.
“We joined Inato's clinical trial community to achieve two goals. First, to bring more suitable clinical trials to the diverse patients in our community and, second, to engage a broader population of patients representing the US within clinical trials,” said Teresa Tocher, director of clinical research at Clinical Trials Management Services.
The importance of access
Inato was able to reveal that during 2022 the company had experienced 210% year-on-year growth in pharmaceutical sponsor adoption. The company outlined that this had been driven by an increased focus on speed and on diversity in clinical trials.
The company cited recent regulatory guidance and pending legislation, such as the Diverse and Equitable Participation in Clinical Trials (DEPICT) Act, as being crucial in emphasizing the importance of access and diversity in clinical trials.
Previously, Inato stated that the top 5% of research sites accounted for approximately 70% of trials. The work the company is doing is to focus on bringing community research sites to the attention of larger industry trials and therefore to grow research outside of these sites, Inato stated.
